Allarity Therapeutics, Inc.
Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045
Patent with 36 allowed claims covering twice-daily treatment in ovarian cancer and other solid tumors
Company newsroom
NASDAQ:ALLR
1 releases
Patent with 36 allowed claims covering twice-daily treatment in ovarian cancer and other solid tumors